Citations (186)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (28)
Jakub Mesinovic, Ayse Zengin, Barbora De Courten, Peter R Ebeling & David Scott. (2019) Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes, Metabolic Syndrome and Obesity 12, pages 1057-1072.
Read now
Read now
Agata Schubert, Anders T. Buchholt, Antoine C. El Khoury, Ahmed Kamal & Vanessa Taieb. (2017) Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. Current Medical Research and Opinion 33:6, pages 1155-1163.
Read now
Read now
Jennifer Hayes, Rosie Anderson & Jeffrey W Stephens. (2016) Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Drug Design, Development and Therapy 10, pages 2263-2270.
Read now
Read now
Marc Evans, Stephen C. Bain & Jiten Vora. (2016) A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology & Metabolism 11:2, pages 217-232.
Read now
Read now
Charles Andy Schuetz, Siew Hwa Ong & Matthias Blüher. (2015) Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. ClinicoEconomics and Outcomes Research 7, pages 313-323.
Read now
Read now
H.L. Katzeff, D. Williams-Herman, L. Xu, G.T. Golm, H. Wang, Q. Dong, J.R. Johnson, E.A. O’Neill, K.D. Kaufman, S.S. Engel & B.J. Goldstein. (2015) Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes. Current Medical Research and Opinion 31:6, pages 1071-1077.
Read now
Read now
Qingwei Zhao, Dongsheng Hong, Dongsheng Zheng, Yao Xiao & Baohua Wu. (2014) Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials. Drug Design, Development and Therapy 8, pages 2283-2294.
Read now
Read now
Antonio Ceriello, Liberata Sportiello, Concetta Rafaniello & Francesco Rossi. (2014) DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opinion on Drug Safety 13:sup1, pages 57-68.
Read now
Read now
Helmut Steinberg, Matt S Anderson, Thomas Musliner, Mary E Hanson & Samuel S Engel. (2013) Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. Vascular Health and Risk Management 9, pages 273-282.
Read now
Read now
Marc Rendell, Andjela Drincic & Radha Andukuri. (2012)
Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 13:4, pages 553-563.
Read now
Read now
Javier Morales. (2011) The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors. Postgraduate Medicine 123:6, pages 189-201.
Read now
Read now
Baptist Gallwitz. (2011) Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 6:4, pages 543-556.
Read now
Read now
Sreevidya Subbarayan & Mark Kipnes. (2011) Sitagliptin: a review. Expert Opinion on Pharmacotherapy 12:10, pages 1613-1622.
Read now
Read now
Paul S. Jellinger. (2011) Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes. Postgraduate Medicine 123:1, pages 53-65.
Read now
Read now
Mansur Shomali. (2011) Add-on therapies to metformin for type 2 diabetes. Expert Opinion on Pharmacotherapy 12:1, pages 47-62.
Read now
Read now
Mary Elizabeth Cox, Jennifer Rowell, Leonor Corsino & Jennifer B Green. (2010) Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety 2, pages 7-19.
Read now
Read now
Karen Barnard, Mary Elizabeth Cox & Jennifer B Green. (2010) Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 3, pages 363-372.
Read now
Read now
André J Scheen. (2010) Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opinion on Drug Metabolism & Toxicology 6:10, pages 1265-1276.
Read now
Read now
Thomas Blevins. (2010) Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes. Postgraduate Medicine 122:1, pages 172-183.
Read now
Read now
Radha Andukuri, Andjela Drincic & Marc Rendell. (2009) Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes, Metabolic Syndrome and Obesity 2, pages 117-126.
Read now
Read now
Anna I. Palalau, Abd A. Tahrani, Milan K. Piya & Anthony H. Barnett. (2009) DPP-4 Inhibitors in Clinical Practice. Postgraduate Medicine 121:6, pages 70-100.
Read now
Read now
Kristen M Kulasa & Robert R Henry. (2009) Pharmacotherapy of hyperglycemia. Expert Opinion on Pharmacotherapy 10:15, pages 2415-2432.
Read now
Read now
F. Xavier Pi-Sunyer. (2009) The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. Postgraduate Medicine 121:5, pages 94-107.
Read now
Read now
Andreas Holstein & Winfried Beil. (2009) Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opinion on Drug Metabolism & Toxicology 5:3, pages 225-241.
Read now
Read now
Debora Williams-Herman, Jeremy Johnson, Rujun Teng, Edmund Luo, Michael J. Davies, Keith D. Kaufman, Barry J. Goldstein & John M. Amatruda. (2009) Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion 25:3, pages 569-583.
Read now
Read now
Bruce Bode & Alpesh Amin. (2009) Incretin-Based Therapies: Review of the Outpatient Literature with Implications for Use in the Hospital and After Discharge. Hospital Practice 37:1, pages 7-21.
Read now
Read now
Joan K Bardsley & Robert E Ratner. (2008) Sitagliptin: an oral agent for glucose control. Expert Review of Endocrinology & Metabolism 3:6, pages 691-697.
Read now
Read now
Jonathan Kent Reynolds, Joshua J Neumiller & R Keith Campbell. (2008) Janumet™: a combination product suitable for use in patients with Type 2 diabetes. Expert Opinion on Investigational Drugs 17:10, pages 1559-1565.
Read now
Read now
Articles from other publishers (158)
Mohamed A. El Hamd, Osama M. Soltan, Kamal S. Abdelrahman, Wejdan T. Alsaggaf & Ahmed A. Abu‐hassan. (2023) A new application of isoindole fluorophore derivative in sitagliptin antidiabetic medication assay: Application to dosage forms and biological fluid evaluation. Luminescence 38:6, pages 744-752.
Crossref
Crossref
R. Patel, N. Parmar, S. P. Palit, N. Rathwa & R. Begum. (2023) A novel combination of sitagliptin and melatonin ameliorates T2D manifestations: studies on experimental diabetic models. Journal of Endocrinological Investigation 46:8, pages 1597-1612.
Crossref
Crossref
Muhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, Raymundo Garcia, Ron S. Newfield, Yulia Samoilova, Carmen A. Rosario, Naim Shehadeh, Chandan K. Saha, Yilong Zhang, Martina Zilli, Lynn W. Scherer, Raymond L. H. Lam, Gregory T. Golm, Samuel S. Engel, Keith D. Kaufman & R. Ravi Shankar. (2021) Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatric Diabetes 23:2, pages 183-193.
Crossref
Crossref
R. Ravi Shankar, Philip Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia, Ron S. Newfield, Yulia Samoilova, Carmen A. Rosario, Naim Shehadeh, Chandan K. Saha, Yilong Zhang, Martina Zilli, Lynn W. Scherer, Raymond L. H. Lam, Gregory T. Golm, Samuel S. Engel & Keith D. Kaufman. (2021) A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Pediatric Diabetes 23:2, pages 173-182.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
199
229
.
AshokK Das, Pramod Gandhi, Banshi Saboo, Sanjay Reddy, Rajeev Chawla, AbdulHamid Zargar, Rajiv Kovil, Manoj Chawla, SK Sharma, Sunil Gupta, BM Makkar, Vinod Mittal, Soumik Goswami, SR Arvind, Shalini Jaggi, Sarita Bajaj & Sambit Das. (2021) Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion. Journal of Family Medicine and Primary Care 10:12, pages 4398.
Crossref
Crossref
Dominik Lautsch, Adnan Alsumali, Euan McLeod, Yuting Kuang, Jing He, Rajpal Singh, Arianna Nevo, Urs Arnet, Jennifer Uyei & Swapnil Rajpathak. (2020) Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis. Diabetes Therapy 12:1, pages 389-418.
Crossref
Crossref
Shubing Jia, Zhiying Wang, Ruobing Han, Zinv Zhang, Yuping Li, Xiaotong Qin, Mingyi Zhao, Rongwu Xiang & Jingyu Yang. (2020) Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. Acta Diabetologica 58:1, pages 5-18.
Crossref
Crossref
Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie & Linong Ji. (2020) Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine 18:1.
Crossref
Crossref
Rania Khalil, Ahmed Shata, Eman M. Abd El-Kader, Hossam Sharaf, Walied S. Abdo, Noha A. Amin & Sameh Saber. (2020) Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling. Toxicology and Applied Pharmacology 407, pages 115246.
Crossref
Crossref
A.J. Scheen. (2020) Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. Diabetes & Metabolism 46:3, pages 186-196.
Crossref
Crossref
Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah & Sheldon W. Tobe. (2019) Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 3:1.
Crossref
Crossref
De-kang Zeng, Qian Xiao, Fa-qi Li, Yu-zhi Tang, Chao-li Jia & Xue-wen Tang. (2019) Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. Bioscience Reports 39:7.
Crossref
Crossref
Iain P. Fraser, Naomi D. Neufeld, Larry A. Fox, Mark S. Kipnes, Tracie L. Miller, Philip S. Zeitler, Henry Rodriguez, Jocelyn H. Gilmartin, Susan J. Lee, Jaclyn K. Patterson, Xiujiang S. Li, Lata Maganti, Wen-Lin Luo, Daniel A. Tatosian & S. Aubrey Stoch. (2019) A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes. Pediatric Diabetes 20:1, pages 48-56.
Crossref
Crossref
Annaswamy Raji, Jianmin Long, Raymond L. H. Lam, Edward A. O’Neill & Samuel S. Engel. (2018) Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials. Diabetes Therapy 9:4, pages 1581-1589.
Crossref
Crossref
Richard E. Pratley, Roy Eldor, Annaswamy Raji, Gregory Golm, Susan B. Huyck, Yanping Qiu, Sheila Sunga, Jeremy Johnson, Steven G. Terra, James P. Mancuso, Samuel S. Engel & Brett Lauring. (2018)
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The
VERTIS FACTORIAL
randomized trial
. Diabetes, Obesity and Metabolism 20:5, pages 1111-1120.
Crossref
Crossref
Sam Miller, Tania Krumins, Haojin Zhou, Susan Huyck, Jeremy Johnson, Gregory Golm, Steven G. Terra, James P. Mancuso, Samuel S. Engel & Brett Lauring. (2018) Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Therapy 9:1, pages 253-268.
Crossref
Crossref
Michael Willmann, Irina Sadovnik, Gregor Eisenwort, Martin Entner, Tina Bernthaler, Gabriele Stefanzl, Emir Hadzijusufovic, Daniela Berger, Harald Herrmann, Gregor Hoermann, Peter Valent & Thomas Rülicke. (2018) Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia. Experimental Hematology 57, pages 50-59.e6.
Crossref
Crossref
Khosro Keshavarz, Farhad Lotfi, Ehsan Sanati, Mahmood Salesi, Amir Hashemi-Meshkini, Mojtaba Jafari, Mohammad M. Mojahedian, Behzad Najafi & Shekoufeh Nikfar. (2017) Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials. DARU Journal of Pharmaceutical Sciences 25:1.
Crossref
Crossref
Xi‐Ling Yang, Mi‐Ma Duo‐Ji & Zi‐Wen Long. (2017) Efficacy and Safety of Single‐ or Double‐Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta‐Analysis. Journal of Cellular Biochemistry 118:12, pages 4536-4547.
Crossref
Crossref
Carolyn T. Bramante, Clare J. Lee & Kimberly A. Gudzune. (2017) Treatment of Obesity in Patients With Diabetes. Diabetes Spectrum 30:4, pages 237-243.
Crossref
Crossref
Islam Y. Elgendy, Ahmed N. Mahmoud, Amr F. Barakat, Akram Y. Elgendy, Marwan Saad, Ahmed Abuzaid, Siddarth A. Wayangankar & Anthony A. Bavry. (2016) Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. American Journal of Cardiovascular Drugs 17:2, pages 143-155.
Crossref
Crossref
Xiafei Lyu, Xiaolin Zhu, Bin Zhao, Liang Du, Dawei Chen, Chun Wang, Guanjian Liu & Xingwu Ran. (2017) Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Scientific Reports 7:1.
Crossref
Crossref
Kayo Fujita, Masayuki Kaneko & Mamoru Narukawa. (2016) Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions. Clinical Drug Investigation 37:3, pages 219-232.
Crossref
Crossref
Alexander Kuhn, Jean Park, Adline Ghazi & Vanita R. Aroda. (2017) Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. Current Cardiology Reports 19:3.
Crossref
Crossref
Subodh Verma, Ronald M. Goldenberg, Deepak L. Bhatt, Michael E. Farkouh, Adrian Quan, Hwee Teoh, Kim A. Connelly, Lawrence A. Leiter & Jan O. Friedrich. (2017) Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open 5:1, pages E152-E177.
Crossref
Crossref
Michael A. Nauck, Melanie Kahle, Oleg Baranov, Carolyn F. Deacon & Jens J. Holst. (2017) Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 19:2, pages 200-207.
Crossref
Crossref
Lingyu He, Shu Liu, Chun Shan, Yingmei Tu, Zhengqing Li & Xiaohua Douglas Zhang. (2016) Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis. BMC Pharmacology and Toxicology 17:1.
Crossref
Crossref
Han Chen, Xiaoying Zhou, Tao Chen, Bingtuan Liu, Wujuan Jin, Huiyuan Gu, Tianyuan Hong & Guoxin Zhang. (2016) Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials. Diabetes Therapy 7:4, pages 725-742.
Crossref
Crossref
S. Kahl. (2016) Kombinationstherapie zweier Inkretinmimetika bei Typ-2-DiabetesCombination therapy of two Incretin mimetics in type 2 diabetes. Der Diabetologe 12:8, pages 578-579.
Crossref
Crossref
Stig Ejdrup Andersen & Mikkel Christensen. (2016) Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. British Journal of Clinical Pharmacology 82:5, pages 1291-1302.
Crossref
Crossref
Robert G. Moses, Elizabeth Round, Yue Shentu, Gregory T. Golm, Edward A. O'neill, Ira Gantz, Samuel S. Engel, Keith D. Kaufman & Barry J. Goldstein. (2016) A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Journal of Diabetes 8:5, pages 701-711.
Crossref
Crossref
W. Gao, Q. Wang & S. Yu. (2016) Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis. Journal of Endocrinological Investigation 39:9, pages 1061-1074.
Crossref
Crossref
Jianying Fu, Jianhong Zhu, Yehua Hao, Chongchong Guo & Zhikun Zhou. (2016) Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Scientific Reports 6:1.
Crossref
Crossref
Helena M. de Wit, Maarten te Groen, Maroeska M. Rovers & Cees J. Tack. (2016)
The placebo response of injectable GLP-1 receptor agonists
vs
. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis
. British Journal of Clinical Pharmacology 82:1, pages 301-314.
Crossref
Crossref
Wenjia Yang, Xiaoling Cai, Xueyao Han & Linong Ji. (2016) DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews 32:4, pages 391-404.
Crossref
Crossref
Je-Yon Kim, Seungwon Yang, Jangik I. Lee & Min Jung Chang. (2016) Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLOS ONE 11:4, pages e0153502.
Crossref
Crossref
Hui WangXiufei LiuMin LongYi HuangLinlin ZhangRui ZhangYi ZhengXiaoyu LiaoYuren WangQian LiaoWenjie LiZili TangQiang TongXiaocui WangFang FangMontserrat Rojo de la VegaQin OuyangDonna D. ZhangShicang YuHongting Zheng. (2016) NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science Translational Medicine 8:334.
Crossref
Crossref
Abdulrahman S. Alanazi. (2015) Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors. Saudi Pharmaceutical Journal 23:6, pages 603-613.
Crossref
Crossref
Giuseppe Derosa, Angela D’Angelo & Pamela Maffioli. (2015) Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. Pharmacological Research 100, pages 127-134.
Crossref
Crossref
R. R. Shankar, L. Xu, G. T. Golm, E. A. O'Neill, B. J. Goldstein, K. D. Kaufman & S. S. Engel. (2015) A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice 69:6, pages 626-631.
Crossref
Crossref
M. E. Rotz, V. S. Ganetsky, S. Sen & T. F. Thomas. (2015) Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice 69:5, pages 531-549.
Crossref
Crossref
Xiaoling Cai, Xueyao Han, Yingying Luo & Linong Ji. (2014)
Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on
β
‐cell function in
A
sian and
C
aucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对
β
细胞功能的影响：一项meta分析
. Journal of Diabetes 7:3, pages 347-359.
Crossref
Crossref
Elizabeth S. Mearns, Diana M. Sobieraj, C. Michael White, Whitney J. Saulsberry, Christine G. Kohn, Yunes Doleh, Eric Zaccaro & Craig I. Coleman. (2015) Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis. PLOS ONE 10:4, pages e0125879.
Crossref
Crossref
Michael A. Nauck & Juris J. Meier. 2015. International Textbook of Diabetes Mellitus. International Textbook of Diabetes Mellitus
726
744
.
James H. Flory & Alvin I. Mushlin. (2015) Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement. Journal of Clinical Epidemiology 68:2, pages 200-210.
Crossref
Crossref
Ji Hyun Kim. (2015) Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal 39:4, pages 304.
Crossref
Crossref
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes & Flávio Reis. (2015) The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?. Journal of Diabetes Research 2015, pages 1-28.
Crossref
Crossref
Chun-Jun Li, Xiao-Juan Liu, Lian Bai, Qian Yu, Qiu-Mei Zhang, Pei Yu & De-Min Yu. (2014) Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetology & Metabolic Syndrome 6:1.
Crossref
Crossref
Shiying Wu, Ingrid Hopper, Marina Skiba & Henry Krum. (2014) Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants. Cardiovascular Therapeutics 32:4, pages 147-158.
Crossref
Crossref
Michael C. Mathers, Sommer D. Zarbock & Emily E. Sutton. (2013) New and Future Medications for the Treatment of Type 2 Diabetes Mellitus. American Journal of Lifestyle Medicine 8:4, pages 260-280.
Crossref
Crossref
R. E. Pratley, P. Fleck & C. Wilson. (2014) Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes, Obesity and Metabolism 16:7, pages 613-621.
Crossref
Crossref
M. Monami, I. Dicembrini & E. Mannucci. (2014) Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 24:7, pages 689-697.
Crossref
Crossref
Xia Liu, Qian Xiao, Li Zhang, Qiao Yang, Xiaoyan Liu, Lingjie Xu & Wen Cheng. (2014) The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18 980 patients with type-2 diabetes mellitus-a meta-analysis. Pharmacoepidemiology and Drug Safety 23:7, pages 687-698.
Crossref
Crossref
강민경, 최경희, 오정미, 정선회 & 김향숙. (2014) Effectiveness and Incidence of Hypoglycemia in the Combination of Sitagliptin and Sulfonylurea, in Patients with Type 2 Diabetes Mellitus. Journal of Korean Society of Health-System Pharmacists 31:3, pages 817-825.
Crossref
Crossref
Shikhar Agarwal, Akhil Parashar & Venu Menon. (2014) Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate. American Journal of Cardiovascular Drugs 14:3, pages 191-207.
Crossref
Crossref
Paul Craddy, Hannah-Jayne Palin & K. Ian Johnson. (2014) Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy 5:1, pages 1-41.
Crossref
Crossref
Paweł Kawalec, Alicja Mikrut & Sylwia Łopuch. (2014) The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews 30:4, pages 269-283.
Crossref
Crossref
Elizabeth M. Round, Samuel S. Engel, Gregory T. Golm, Michael J. Davies, Keith D. Kaufman & Barry J. Goldstein. (2014) Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies. Drugs & Aging 31:3, pages 203-214.
Crossref
Crossref
Greg L. Plosker. (2014) Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:2, pages 223-242.
Crossref
Crossref
Fatemeh Hayati, Amjed Hazim, Teguh Haryo Sasongko, Gan Siew Hua, Wan Mohd Izani Wan Mohamed, Juhaida Daud, Nik Soriani Yaacob & Wan Mohamad Wan Bebakar. (2014) Efficacy and safety of sitagliptin as a third therapeutic agent in the treatment of type 2 diabetes mellitus. Journal of Diabetes Research and Clinical Metabolism 3:1, pages 10.
Crossref
Crossref
Sri Harsha Tella, Halis Kaan Akturk & Marc Rendell. (2014) Linagliptin for the treatment of Type 2 diabetes. Diabetes Management 4:1, pages 85-101.
Crossref
Crossref
M. Monami, I. Dicembrini & E. Mannucci. (2014) Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 16:1, pages 48-56.
Crossref
Crossref
Sung-Chen Liu, Kuo-Liong Chien, Chao-Hung Wang, Wei-Che Chen & Ching-Hsiang Cleunghen. (2013) Efficacy and Safety of Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Insufficiently Controlled with Metformin and a Sulfonylurea. Endocrine Practice 19:6, pages 980-988.
Crossref
Crossref
Naoko Tajima, Takashi Kadowaki, Taro Okamoto, Asako Sato, Kotoba Okuyama, Toshiomi Minamide & Juan Camilo Arjona Ferreira. (2013) Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. Journal of Diabetes Investigation 4:6, pages 595-604.
Crossref
Crossref
Takashi Kadowaki, Naoko Tajima, Masato Odawara, Toshiomi Minamide, Masaru Kawashima, Daisuke Yanagida, Taro Okamoto & Juan Camilo Arjona Ferreira. (2013) Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetology International 4:3, pages 160-172.
Crossref
Crossref
R. E. van Genugten, D. L. Möller‐Goede, D. H. van Raalte & M. Diamant. (2013) Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes. Diabetes, Obesity and Metabolism 15:7, pages 593-606.
Crossref
Crossref
Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman & Barry J. Goldstein. (2013) Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy 4:1, pages 119-145.
Crossref
Crossref
Takanobu Shimasaki, Takayuki Masaki, Kimihiko Mitsutomi, Daisuke Ueno, Koro Gotoh, Seiichi Chiba, Tetsuya Kakuma & Hironobu Yoshimatsu. (2013) The Dipeptidyl Peptidase-4 Inhibitor Des-Fluoro-Sitagliptin Regulates Brown Adipose Tissue Uncoupling Protein Levels in Mice with Diet-Induced Obesity. PLoS ONE 8:5, pages e63626.
Crossref
Crossref
Stefano Del Prato, Marja-Riitta Taskinen, David R. Owens, Maximilian von Eynatten, Angela Emser, Yan Gong, Silvia Chiavetta, Sanjay Patel & Hans-Juergen Woerle. (2013) Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials. Journal of Diabetes and its Complications 27:3, pages 274-279.
Crossref
Crossref
Y. G. Kim, S. Hahn, T. J. Oh, S. H. Kwak, K. S. Park & Y. M. Cho. (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56:4, pages 696-708.
Crossref
Crossref
Takashi Kadowaki, Naoko Tajima, Masato Odawara, Mikio Nishii, Tadaaki Taniguchi & Juan Camilo Arjona Ferreira. (2012)
Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in
J
apanese patients with type 2 diabetes over 52 weeks
. Journal of Diabetes Investigation 4:2, pages 174-181.
Crossref
Crossref
Adrian S. DOBS, Barry J. GOLDSTEIN, Pablo ASCHNER, Edward S. HORTON, Guillermo E. UMPIERREZ, Lorraine DURAN, Julie S. HILL, Yu CHEN, Gregory T. GOLM, Ronald B. LANGDON, Debora E. WILLIAMS-HERMAN, Keith D. KAUFMAN, John M. AMATRUDA & Juan Camilo ARJONA FERREIRA. (2013) Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*. Journal of Diabetes 5:1, pages 68-79.
Crossref
Crossref
Chitrabhanu BallavStephen C.L. Gough. (2013) Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes 6, pages CMED.S7314.
Crossref
Crossref
Samuel S Engel, Gregory T Golm, Deborah Shapiro, Michael J Davies, Keith D Kaufman & Barry J Goldstein. (2013) Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovascular Diabetology 12:1, pages 3.
Crossref
Crossref
Michael Cobble. (2012) Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 4:1.
Crossref
Crossref
K. Gooßen & S. Gräber. (2012) Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:12, pages 1061-1072.
Crossref
Crossref
Richard M. Bergenstal, Adriana Forti, Jean-Louis Chiasson, Michael Woloschak, Mark Boldrin & Raffaella Balena. (2012) Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial). Diabetes Therapy 3:1.
Crossref
Crossref
Haesuk Park, Chanhyun Park, Yoona Kim & Karen L Rascati. (2012) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis. Annals of Pharmacotherapy 46:11, pages 1453-1469.
Crossref
Crossref
Richard E. Pratley, Michael A. Nauck, Timothy Bailey, Eduard Montanya, Sebastiano Filetti, Alan J. Garber, Anne B. Thomsen, Sabina Furber & Melanie Davies. (2012) Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care 35:10, pages 1986-1993.
Crossref
Crossref
S. Cornell. (2012) Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics 37:5, pages 510-524.
Crossref
Crossref
Giuseppe Derosa, Anna Carbone, Ivano Franzetti, Fabrizio Querci, Elena Fogari, Lucio Bianchi, Aldo Bonaventura, Davide Romano, Arrigo F.G. Cicero & Pamela Maffioli. (2012) Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Research and Clinical Practice 98:1, pages 51-60.
Crossref
Crossref
Wenying YANG, Yanfen GUAN, Yue SHENTU, Zhi LI, Amy O. JOHNSON-LEVONAS, Samuel S. ENGEL, Keith D. KAUFMAN, Barry J. GOLDSTEIN & Maria ALBA. (2012)
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*
†
. Journal of Diabetes 4:3, pages 227-237.
Crossref
Crossref
S.‐C. Liu, Y.‐K. Tu, M.‐N. Chien & K.‐L. Chien. (2012) Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta‐analysis. Diabetes, Obesity and Metabolism 14:9, pages 810-820.
Crossref
Crossref
Mei Zhan, Ting Xu, Fengbo Wu & Yao Tang. (2012) Sitagliptin in the treatment of type 2 diabetes: a meta‐analysis. Journal of Evidence-Based Medicine 5:3, pages 154-165.
Crossref
Crossref
C. F. Deacon, E. Mannucci & B. Ahrén. (2012) Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis. Diabetes, Obesity and Metabolism 14:8, pages 762-767.
Crossref
Crossref
Brenda Capaldi. (2012) Incretin therapies for type 2 diabetes: what nurses need to know. Nurse Prescribing 10:7, pages 345-352.
Crossref
Crossref
K. R. Gerrald, E. Van Scoyoc, R. C. Wines, T. Runge & D. E. Jonas. (2011) Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:6, pages 481-492.
Crossref
Crossref
Vanita R. Aroda, Robert R. Henry, Jenny Han, Wenying Huang, Mary Beth DeYoung, Tamara Darsow & Byron J. Hoogwerf. (2012) Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics 34:6, pages 1247-1258.e22.
Crossref
Crossref
J. Wainstein, L. Katz, S. S. Engel, L. Xu, G. T. Golm, S. Hussain, E. A. O’Neill, K. D. Kaufman & B. J. Goldstein. (2011) Initial therapy with the fixed‐dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 14:5, pages 409-418.
Crossref
Crossref
Hajime Maeda, Akira Kubota, Yasushi Tanaka, Yasuo Terauchi & Ikuro Matsuba. (2012) The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Research and Clinical Practice 95:1, pages e20-e22.
Crossref
Crossref
Roger S. Mazze, Ellie S. Strock, Richard M. Bergenstal, Amy Criego, Robert Cuddihy, Oded Langer, Gregg D. Simonson & Margaret A. Powers. 2011. Staged Diabetes Management. Staged Diabetes Management
77
137
.
B. Vergès, C. Bonnard & E. Renard. (2011) Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes & Metabolism 37:6, pages 477-488.
Crossref
Crossref
Atsunori Kashiwagi, Takashi Kadowaki, Naoko Tajima, Kenji Nonaka, Tadaaki Taniguchi, Mikio Nishii, Juan Camilo Arjona Ferreira & John M Amatruda. (2011) Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation 2:5, pages 381-390.
Crossref
Crossref
Stanley H. Hsia, Maria D. Navar, Petra Duran, Magda Shaheen & Mayer B. Davidson. (2011) Sitagliptin Compared with Thiazolidinediones as a Third-Line Oral Antihyperglycemic Agent in Type 2 Diabetes Mellitus. Endocrine Practice 17:5, pages 691-698.
Crossref
Crossref
A. Pérez-Monteverde, T. Seck, L. Xu, M. A. Lee, C. M. Sisk, D. E. Williams-Herman, S. S. Engel, K. D. Kaufman & B. J. Goldstein. (2011) Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. International Journal of Clinical Practice 65:9, pages 930-938.
Crossref
Crossref
Susan J. Appel. (2011) Apuntes sobre la terapia basada en la incretina para la diabetes tipo 2. Nursing (Ed. española) 29:7, pages 27-28.
Crossref
Crossref
Roberta Baetta & Alberto Corsini. (2011) Pharmacology of Dipeptidyl Peptidase-4 Inhibitors. Drugs 71:11, pages 1441-1467.
Crossref
Crossref
C. Reasner, L. Olansky, T. L. Seck, D. E. Williams-Herman, M. Chen, L. Terranella, A. O. Johnson-Levonas, K. D. Kaufman & B. J. Goldstein. (2011) The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 13:7, pages 644-652.
Crossref
Crossref
K. Esposito, D. Cozzolino, G. Bellastella, M. I. Maiorino, P. Chiodini, A. Ceriello & D. Giugliano. (2011) Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 13:7, pages 594-603.
Crossref
Crossref
Joshua J. Neumiller. (2011) Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment. Clinical Therapeutics 33:5, pages 528-576.
Crossref
Crossref
Matteo Monami, Francesco Cremasco, Caterina Lamanna, Niccolò Marchionni & Edoardo Mannucci. (2011) Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials. Diabetes/Metabolism Research and Reviews 27:4, pages 362-372.
Crossref
Crossref
Anthony H. Barnett. (2011) New treatments for type 2 diabetes in the UK – An evolving landscape. Primary Care Diabetes 5:1, pages 1-7.
Crossref
Crossref
Travis E Sonnett, Jennifer D Robinson & Kurt A Bowen. (2011) Incretin-based therapies and their future in Type 2 diabetes mellitus. Therapy 8:2, pages 143-152.
Crossref
Crossref
B. Ahrén, J. E. Foley & E. Bosi. (2011) Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes, Obesity and Metabolism 13:3, pages 193-203.
Crossref
Crossref
Susan J. Appel. (2011) Tapping incretin-based therapy for type 2 diabetes. Nursing 41:3, pages 49-51.
Crossref
Crossref
Carolyn Robertson. (2011) Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. Diabetes Spectrum 24:1, pages 26-35.
Crossref
Crossref
Claudine M. Chwieduk. (2011) Sitagliptin/Metformin Fixed-Dose Combination. Drugs 71:3, pages 349-361.
Crossref
Crossref
K. H. Yoon, G. R. Shockey, R. Teng, G. T. Golm, P. R. Thakkar, A. G. Meehan, D. E. Williams-Herman, K. D. Kaufman, J. M. Amatruda & H. Steinberg. (2011) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. International Journal of Clinical Practice 65:2, pages 154-164.
Crossref
Crossref
R. Arechavaleta, T. Seck, Y. Chen, K. J. Krobot, E. A. O’Neill, L. Duran, K. D. Kaufman, D. Williams-Herman & B. J. Goldstein. (2011) Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism 13:2, pages 160-168.
Crossref
Crossref
B. Charbonnel & B. Cariou. (2011) Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes, Obesity and Metabolism 13:2, pages 99-117.
Crossref
Crossref
Kathryn MS JohnsonKathleen Schurr. (2011) Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6227.
Crossref
Crossref
Won Jun KimCheol-Young ParkEun Haeng JeongJeong Youn SeoJi Soo SeolSe Eun ParkEun Jung RheeWon Young LeeKi Won OhSung Woo ParkSun Woo Kim. (2011) Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration. Diabetes & Metabolism Journal 35:3, pages 290.
Crossref
Crossref
M.-R. Taskinen, J. Rosenstock, I. Tamminen, R. Kubiak, S. Patel, K. A. Dugi & H.-J. Woerle. (2011) Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism 13:1, pages 65-74.
Crossref
Crossref
Bernard Zinman. (2011) Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?. The American Journal of Medicine 124:1, pages S19-S34.
Crossref
Crossref
Michael A. Nauck. (2011) Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications. The American Journal of Medicine 124:1, pages S3-S18.
Crossref
Crossref
Jaime A. Davidson. (2010) Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. Mayo Clinic Proceedings 85:12, pages S27-S37.
Crossref
Crossref
Debora Williams-Herman, Samuel S Engel, Elizabeth Round, Jeremy Johnson, Gregory T Golm, Hua Guo, Bret J Musser, Michael J Davies, Keith D Kaufman & Barry J Goldstein. (2010) Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders 10:1.
Crossref
Crossref
T. Forst, B. Uhlig-Laske, A. Ring, U. Graefe-Mody, C. Friedrich, K. Herbach, H.-J. Woerle & K. A. Dugi. (2010) Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabetic Medicine 27:12, pages 1409-1419.
Crossref
Crossref
Elizabeth M. Migoya, Jutta L. Miller, Maria Gutierrez, Wei Zheng, Amy O. Johnson-Levonas, Qi Liu, Catherine Z. Matthews, John A. Wagner & Keith M. Gottesdiener. (2012) Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects. Clinical Drug Investigation 30:12, pages 855-866.
Crossref
Crossref
John Gerich. (2010) DPP-4 inhibitors: What may be the clinical differentiators?. Diabetes Research and Clinical Practice 90:2, pages 131-140.
Crossref
Crossref
Sherwyn L. Schwartz. (2010) Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. The American Journal of Geriatric Pharmacotherapy 8:5, pages 405-418.
Crossref
Crossref
André J. Scheen, Guillaume Charpentier, Carl Johan Östgren, Åsa Hellqvist & Ingrid Gause-Nilsson. (2010) Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews 26:7, pages 540-549.
Crossref
Crossref
Gerald Gartlehner, Andrea Chapman, Michaela Strobelberger & Kylie Thaler. (2010) Differences in Efficacy and Safety of Pharmaceutical Treatments between Men and Women: An Umbrella Review. PLoS ONE 5:7, pages e11895.
Crossref
Crossref
David Haslam. (2010) Obesity and diabetes: the links and common approaches. Primary Care Diabetes 4:2, pages 105-112.
Crossref
Crossref
Scott R. Drab. (2012) Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30:6, pages 609-624.
Crossref
Crossref
Joshua J Neumiller, Lindy Wood & R. Keith Campbell. (2010) Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Pharmacotherapy 30:5, pages 463-484.
Crossref
Crossref
I. W. Campbell. (2010) Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?. International Journal of Clinical Practice 64:6, pages 791-801.
Crossref
Crossref
M. Monami, I. Iacomelli, N. Marchionni & E. Mannucci. (2010) Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 20:4, pages 224-235.
Crossref
Crossref
Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak & Edwin E Salpeter. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
T. Seck, M. Nauck, D. Sheng, S. Sunga, M. J. Davies, P. P. Stein, K. D. Kaufman & J. M. Amatruda. (2010) Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. International Journal of Clinical Practice 64:5, pages 562-576.
Crossref
Crossref
Sohita Dhillon. (2010) Sitagliptin. Drugs 70:4, pages 489-512.
Crossref
Crossref
Michael A Nauck & Irfan Vardarli. (2010) Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure†. Journal of Diabetes Investigation 1:1-2, pages 24-36.
Crossref
Crossref
Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak & Edwin E Salpeter (posthumous). 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Scott P. Rigby, Yehuda Handelsman, Yu-Ling Lai, Stacey L. Abby, Ben Tao & Michael R. Jones. (2010) Effects of Colesevelam, Rosiglitazone, or Sitagliptin on Glycemic Control and Lipid Profile in Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin Monotherapy. Endocrine Practice 16:1, pages 53-63.
Crossref
Crossref
David Russell-Jones. (2010) Current developments in the treatment of diabetes: the incretin therapies. The British Journal of Diabetes & Vascular Disease 10:1, pages 21-30.
Crossref
Crossref
B. Gallwitz & H.‐U. Häring. (2009) Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP‐4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 12:1, pages 1-11.
Crossref
Crossref
Mark KirbyDenise M.T. Yu, Steven O'connorMark D. Gorrell. (2009) Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clinical Science 118:1, pages 31-41.
Crossref
Crossref
Heiner C. Bucher. (2010) Nutzen und Grenzen von Studien mit Surrogat-Endpunkten in der klinischen Entscheidungsfindung. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 104:3, pages 230-237.
Crossref
Crossref
Jochen Seufert. (2009) The backbone of oral glucose-lowering therapy: time for a paradigm shift?. Fundamental & Clinical Pharmacology 23:6, pages 651-667.
Crossref
Crossref
Carolyn Robertson. (2009) New developments in incretin-based therapies: The current state of the field. Journal of the American Academy of Nurse Practitioners 21, pages 631-641.
Crossref
Crossref
D. Hamish Wright, Gary A. Herman, Andrea Maes, Qi Liu, Amy O. Johnson-Levonas & John A. Wagner. (2009) Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin. The Journal of Clinical Pharmacology 49:10, pages 1157-1167.
Crossref
Crossref
M. Nauck & U. Smith. (2009) Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?. Best Practice & Research Clinical Endocrinology & Metabolism 23:4, pages 513-523.
Crossref
Crossref
Jing Wu, Yiding Chen, Xiaoli Shi & Wei Gu. (2009) Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes. Journal of Nanjing Medical University 23:4, pages 228-235.
Crossref
Crossref
Aberra Fura, Ashish Khanna, Viral Vyas, Barry Koplowitz, Shu-Ying Chang, Christian Caporuscio, David W. Boulton, Lisa J. Christopher, Kristina D. Chadwick, Lawrence G. Hamann, W. Griffith Humphreys & Mark Kirby. (2009) Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections. Drug Metabolism and Disposition 37:6, pages 1164-1171.
Crossref
Crossref
D Russell‐Jones. (2009) The role of incretin‐based therapies in the management of type 2 diabetes. Practical Diabetes International 26:5, pages 186.
Crossref
Crossref
AH Barnett. (2009) Treatment options for type 2 diabetes:introducing the incretin‐based therapies. Practical Diabetes International 26:5, pages 179.
Crossref
Crossref
Matthew Potenza & Elliot J. Rayfield. (2009) Targeting the Incretin System in Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:3, pages 244-256.
Crossref
Crossref
Daniel M. Riche, Honey E. East & Krista D. Riche. (2009) Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis. The American Journal of the Medical Sciences 337:5, pages 321-328.
Crossref
Crossref
Julie A. Lovshin & Daniel J. Drucker. (2009) Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology 5:5, pages 262-269.
Crossref
Crossref
Leonor CorsinoMary Elizabeth CoxJennifer RowellJennifer B. Green. (2009) Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. Clinical Medicine. Therapeutics 1, pages CMT.S2109.
Crossref
Crossref
M. A. Nauck, G. C. Ellis, P. R. Fleck, C. A. Wilson & Q. Mekki. (2009) Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. International Journal of Clinical Practice 63:1, pages 46-55.
Crossref
Crossref
Viswanathan Mohan, Wenying Yang, Ho-Young Son, Lei Xu, Liliane Noble, Ronald B. Langdon, John M. Amatruda, Peter P. Stein & Keith D. Kaufman. (2009) Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Research and Clinical Practice 83:1, pages 106-116.
Crossref
Crossref
Debora Williams-Herman, Elizabeth Round, Arlene S Swern, Bret Musser, Michael J Davies, Peter P Stein, Keith D Kaufman & John M Amatruda. (2008) Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders 8:1.
Crossref
Crossref
Emanuele Bosi, Pietro Lucotti, Emanuela Setola, Lucilla Monti & Pier Marco Piatti. (2008) Incretin-based therapies in type 2 diabetes: A review of clinical results. Diabetes Research and Clinical Practice 82, pages S102-S107.
Crossref
Crossref
Javaid H. Wani, Jennifer John-Kalarickal & Vivian A. Fonseca. (2008) Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review. Cardiology Clinics 26:4, pages 639-648.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:9.
Crossref
Crossref
H.C. Bucher. (2008) Studien mit SurrogatendpunktenSurrogate endpoint trials: Benefit and pitfalls for clinical decision making. Der Internist 49:6, pages 681-687.
Crossref
Crossref